TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18946484
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg day(-1)
Study: 18946484
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg day(-1)
Study: 18946484
Drug: Rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine 1 mg day(-1)
Study: 12580984
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg day(-1)
Study: 17467226
Drug: Medical compression
Normalized name: Truform Medical Compression Stockings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical compression stockings (23 to 32 mm Hg) worn daily for 3 weeks
Study: 9855323
Drug: Filgrastim administration
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim administration after chemotherapy
Study: 9855323
Drug: Chemotherapy started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy started within 72 hours of filgrastim therapy
Study: 7907729
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (500 mg/m2, three times a day for 1 month) followed by oral acyclovir (800 mg four times a day for 6 months)
Study: 7907729
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir followed by oral placebo
Study: 7907729
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral acyclovir (200 or 400 mg, four times a day) followed by placebo
Study: 2534054
Drug: Ipratropium (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (80 micrograms applied intranasally four times daily)
Study: 7352836
Drug: Short-acting oral
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting oral fluphenazine hydrochloride
Study: 10335757
Drug: Cerivastatin 0.8
Normalized name: cerivastatin 0.8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.8 mg daily
Study: 2020613
Drug: Bromfenac 25
Normalized name: bromfenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 25 mg and Ibuprofen 400 mg
Study: 6982803
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) tablets, 0.5 mg, four times daily for five days
Study: 26489809
Drug: Amiloride 10
Normalized name: amiloride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 10 mg daily (doubled after 12 weeks)
Study: 26489809
Drug: Amiloride plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride plus Hydrochlorothiazide (5 mg + 12.5 mg daily, doubled after 12 weeks)
Study: 26489809
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg daily (doubled after 12 weeks)
Study: 25016507
Drug: ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.5% (0.5 mL/kg)
Study: 25016507
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2% (0.5 mL/kg)
Study: 22653094
Drug: Eperisone with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone with tramadol (100 mg/day)
Study: 22653094
Drug: Tizanidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine with tramadol (100 mg/day)
Study: 23140090
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg etoricoxib
Study: 11954883
Drug: Intra-articular lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lavage with 5 l of physiological fluid
Study: 11954883
Drug: Intra-articular lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lavage with 10 l of physiological fluid
Study: 11954883
Drug: Intra-articular lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lavage with 0.5-1.5 l of physiological fluid
Study: 10512405
Drug: Rifampin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin, 10 mg/kg per day in two divided doses for 18+/‐20 months
Study: 8554930
Drug: L-NMMA infusion
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA infusion (0.1, 0.2, 0.5, 1.0 and 2.0 mg kg‐1 h‐1)
Study: 27270566
Drug: L-NMMA infusion
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA infusion
Study: 8737105
Drug: Metoprolol 50-100
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol 50-100 mg b.i.d. (n = 106)
Study: 8737105
Drug: Xamoterol 100-200
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 100-200 mg b.i.d. (n = 104)
Study: 6397848
Drug: De-Nol tablets
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-Nol tablets (four times daily)
Study: 6397848
Drug: Cimetidine tablets
Normalized name: Cimetidine Tablets
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine tablets (400 mg, twice daily)
Study: 6397848
Drug: De-Nol tablets
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-Nol tablets
Study: 30664828
Drug: 15 keto
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 keto fluprostenol isopropyl ester gel (80 µgr/mL)
Study: 26034917
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with aspirin
Study: 2866134
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg twice daily
Study: 17570951
Drug: Olanzapine (14.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (14.0 +/- 5.0 mg/day)
Study: 17570951
Drug: Perazine (360.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perazine (360.0 +/- 196.0 mg/day) + Carbamazepine (404.0 +/- 229.0 mg/day)
Study: 15549464
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (5 times)
Study: 15549464
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (10 times)
Study: 15549464
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 1 ml)
Study: 11298666
Drug: Cyclandelate (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (1600 mg)
Study: 29885752
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral health education
Study: 31812463
Drug: Intranasal influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal influenza vaccine with 30 μg LTh(αK) adjuvant (group 1)
Study: 31812463
Drug: Intranasal influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal influenza vaccine with 45 μg LTh(αK) adjuvant (group 2)
Study: 31812463
Drug: Intranasal influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal influenza vaccine with 22.5 μg HA antigen alone (control group 3)
Study: 25985907
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus atorvastatin 10 mg
Study: 25985907
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change in therapy
Study: 25985907
Drug: Double atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double atorvastatin dose
Study: 25985907
Drug: Physicians' treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians' treatment recommendations
Study: 23729226
Drug: Netupitant with
Normalized name: Netupitant
DrugBank: Netupitant (DB09048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netupitant with dexamethasone (300 mg)
Study: 19951408
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg daily of chicken type II collagen (CCII)
Study: 19951408
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg once a week of methotrexate (MTX)
Study: 12846051
Drug: 7.5‐15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5‐15 mg of prednisolone (PRE) daily for one to three months followed by methotrexate (MTX) 5‐15 mg weekly if needed
Study: 12846051
Drug: sulfasalazine (SAL),
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfasalazine (SAL), supplemented with lowest possible corticosteroid dose if needed
Study: 8601981
Drug: Erythromycin lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin lactobionate (200 mg in 50 ml normal saline solution intravenously)
Study: 8601981
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 ml normal saline solution intravenously)
Study: 1761642
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIG), 400 mg/kg daily for 3 days
Study: 7346177
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) treatment, given b.i.d. (twice daily)
Study: 7346177
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) treatment, with dose reduction
Study: 2547950
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 to 40 mg daily)
Study: 3002672
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 to 240 mg daily)
Study: 3400680
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose regimen
Study: 26482590
Drug: Radiofrequency-targeted Vertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency-targeted Vertebral Augmentation (RF-TVA)
Study: 23012836
Drug: Diphenhydramine 1
Normalized name: diphenhydramine 18.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 1 mg x kg(‐1) intravenously
Study: 20047897
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physostigmine and alfentanil (same doses)
Study: 20047897
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physostigmine and alfentanil
Study: 14759321
Drug: Ceftriaxone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (50 mg/kg, total dose < 1 g) injected once
Study: 14759321
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg/(kg.d), tid) for 10 days
Study: 10233203
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg racemic ibuprofen
Study: 10233203
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg racemic ibuprofen
Study: 8942221
Drug: Cefuroxime (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (750 mg i.v. 8H for 48 H/500 mg p.o bid)
Study: 8942221
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (1.2 g i.v. 8 H for 48 H/750 mg p.o. tid)
Study: 1763562
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (microspheres of size 1.0-1.2 mm)
Study: 1763562
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (microspheres of size 1.8-2.0 mm)
Study: 22678699
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 800 mg bid for 6 weeks
Study: 17986636
Drug: PF-00915275 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00915275 (15 mg)
Study: 17986636
Drug: PF-00915275 (0.3-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00915275 (0.3-15 mg)
Study: 15664001
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin therapy (200 IU nasal spray daily during alternate months) + 400 IU Vitamin D + 1000 mg elemental calcium
Study: 11307041
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg oral dose
Study: 1930053
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg every 6 h)
Study: 22014374
Drug: Low baseline
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low baseline vitamin D (<32 ng/ml) concentrations
Study: 16905572
Drug: Oestradiol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (2.5 mg/kg/day) and progesterone (22.5 mg/kg/day) given by continuous intravenous infusion of a standard lipid emulsion (15 ml/kg/day)
Study: 16244006
Drug: Gabapentin, eutectic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound
Study: 11952769
Drug: Tiagabine (TGB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (TGB; Gabitril) 32 or 56 mg daily
Study: 10374370
Drug: Artemether (Art)
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether (Art) - 6 mg/kg, administered every 15 days if continued exposure, with an additional dose 7-15 days after withdrawal from pilot.
Study: 2765151
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment methods
Study: 1102887
Drug: Trivastal (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivastal (1 dragee daily, increasing to 3-6 dragees over 14 weeks)
Study: 26241253
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline injection
Study: 10967266
Drug: Antiresorptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive therapy (30 mg pamidronate IV every 3 months, n = 14)
Study: 10967266
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy (n = 5)
Study: 10967266
Drug: Antiresorptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive therapy (pamidronate or HRT)
Study: 8829118
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion alone
Study: 8829118
Drug: Furosemide infusion
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide infusion alone
Study: 8829118
Drug: Furosemide and
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide and dopamine infusions administered concurrently
Study: 7949627
Drug: TBARM in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBARM in ALI patients (3.05 +/‐ 0.65 nMol/ml)
Study: 7949627
Drug: 7S collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7S collagen in ALI patients (9.06 +/‐ 5.96 ng/ml)
Study: 23386159
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) pethidine
Study: 20959965
Drug: Multifactorial evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial evaluation and treatment of fall risk factors
Study: 9118614
Drug: GM-CSF 300
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF 300 U/d on days 8 and 15 post-chemotherapy for neutropenia prophylaxis
Study: 1999086
Drug: Ciprofloxacin 300
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin 300 mg i.v. every 12 hours for pneumonia
Study: 1999086
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g i.v. every eight hours for pneumonia
Study: 1999086
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg i.v. every 12 hours for UTI
Study: 1999086
Drug: Ceftazidime 1
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1 g i.v. every eight hours for UTI
Study: 31690602
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training (2-year duration, 2 weekly sessions: 5 min warm-up, 20 min aerobic training, 30 min resistance training, 20 min core stability, balance and flexibility training with weighted vests)
Study: 25746777
Drug: self‐administered mCBT‐I
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐administered mCBT‐I (n=20; 6 short booklets + 3 phone consultations with a psychologist, over 6 weeks)
Study: 25746777
Drug: no‐treatment condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: no‐treatment condition (n=18)
Study: 23403498
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/d) with hormone therapy (HT)
Study: 23403498
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with hormone therapy (HT)
Study: 21788220
Drug: Propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride 2 mg/kg per day divided 3 times daily for 6 months
Study: 16257815
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: 15007574
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G
Study: 9728835
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 50 or 150 microg
Study: 795439
Drug: Dexatopic ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexatopic ointment (17 beta‐hydroxy‐4‐estren‐3‐one‐17‐decanoate)
Study: 314399
Drug: Reference ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference ointment
Study: 31628586
Drug: L-carnitine (500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (500-mg tablet, 2-3 times daily)
Study: 28981445
Drug: Honey cream
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey cream
Study: 26488737
Drug: Phenytoin cream
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin cream
Study: 25678778
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of gemigliptin/metformin 25/500 mg
Study: 25678778
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of gemigliptin (50 mg) and metformin XR (500 mg)
Study: 20099536
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral treatment
Study: 16760174
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) followed by 6‐month treatment with 3 MU thrice weekly of highly purified natural interferon‐alpha (n = 128; arm A)
Study: 16760174
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (n = 124; arm B)
Study: 11297592
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg moclobemide for 75 days
Study: 11297592
Drug: Oral fluocortolone
Normalized name: fluocortolone
DrugBank: Fluocortolone (DB08971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluocortolone (tapered until day 29)
Study: 27329280
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray (all doses)
Study: 15755389
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of flu vaccine (FV)
Study: 15755389
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of flu vaccine (FV)
Study: 1851340
Drug: Zileuton (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (800 mg, single oral dose)
Study: 6996072
Drug: Diflunisal (0.5‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (0.5‐1 g/day)
Study: 6996072
Drug: Aspirin (2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2‐4 g/day)
Study: 26062186
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion treatment applied twice a week for 8 weeks.
Study: 17439907
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (GB), 120 mg twice a day for 12 weeks
Study: 2766313
Drug: Habitual oral
Normalized name: Habitrol Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habitual oral hygiene
Study: 939970
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy totaling 4000 to 4500 rads in 4 to 5 weeks (Group 1)
Study: 939970
Drug: 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) 130 mg/sq m orally every 6 weeks (Group 2)
Study: 939970
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus CCNU (Group 3)
Study: 16133077
Drug: 0.35% povidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35% povidone-iodine solution followed by normal saline solution
Study: 1361775
Drug: Dextrose only
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose only (usual treatment) for 4 weeks
Study: 27356701
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to classical songs through headphones)